AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

PharmaGap Inc (GAP) provides guidance on timing of testing at National Cancer Institute.

Chemical Business Newsbase

| May 07, 2009 | COPYRIGHT 2000 Elsevier Engineering Information, Inc. (Hide copyright information)Copyright

PharmaGap Inc announced that the National Cancer Institute (NCI) has confirmed receipt of PharmaGap's drug product PhG-alpha-1 at its drug depository in Rockville, MD, in advance of testing in the NCI's tumour cell panel consisting of 60 human cancer cell lines. The NCI has advised the company that the …

Related articles from newspapers, magazines, journals, and more
Roswell Park Cancer Institute.(joins National Cancer Institute ovarian cancer...
Magazine article from: Business First of Buffalo February 12, 2001 700+ words
GRANTS.(University of Pittsburgh Cancer Institute receives National Cancer...
Magazine article from: Pittsburgh Business Times July 27, 2001 700+ words
Genex Corp.: protein proves successful in Cancer Institute's tests. (the...
Magazine article from: Washington Business Journal July 30, 1990 700+ words
Screening for agents against the human immunodeficiency virus. (National...
Newspaper article from: AIDS Weekly June 22, 1992 700+ words
National Cancer Institute OKs contract for data support. (Orkand Corp.)
Magazine article from: Washington Business Journal November 12, 1990 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily